Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;48(5):4421-4429.
doi: 10.1007/s11033-021-06461-3. Epub 2021 Jun 15.

Serum fatty acid binding protein 5 (FABP5) as a potential biomarker of inflammation in psoriasis

Affiliations

Serum fatty acid binding protein 5 (FABP5) as a potential biomarker of inflammation in psoriasis

Dorota Kozłowska et al. Mol Biol Rep. 2021 May.

Abstract

Fatty acid binding protein 5 (FABP5) is elevated in psoriatic keratinocytes and could be involved in systemic metabolic disturbances in psoriasis. The aim of the study was to evaluate serum FABP5 in obese and non-obese psoriatic patients, to assess the relationship between FABP5 and the duration, severity of the disease, inflammatory and metabolic markers and influence of treatment with narrowband-ultraviolet B (NB-UVB). Seventy-four patients (30 treated with NB-UVB) with psoriasis were enrolled in the study. The serum concentrations of FABP5 were measured using Human FABP5 Enzyme-Linked Immunosorbent Assay kit. Serum fatty acids were measured by gas-liquid chromatography. Serum FABP5 levels in psoriatic patients were higher versus control group (P < 0.001). FABP5 in patients with PASI > 20 was higher compared to the mild group (PASI < 10) (P < 0.001) and serum FABP5 correlated positively with PASI score (r = 0.41, P < 0.001). There was also positive correlation between FABP5 and basic inflammation indices. Decrease of PASI after NB-UVB treatment (P < 0.001) was observed and accompanied by decrease of the serum FABP5 (P = 0.007). FABP5 is a potential marker of psoriasis, its severity and clinical outcome after therapy with NB-UVB. FABP5 may reflect metabolic disturbances in psoriatic patients.

Keywords: Epidermal fatty acid binding protein; Fatty acid binding protein 5; Lipid disturbances; Metabolic syndrome; Narrowband—ultraviolet B; Psoriasis.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Comparison of serum fatty acid binding protein 5 (FABP5) concentration between patients and controls. Data shown as median and quartiles (Q1, Q3). Significant difference between the groups P < 0.001 *** (n = 74)
Fig. 2
Fig. 2
Comparison of serum fatty acid binding protein 5 (FABP5) concentrations between patients according to the severity of the disease. Data shown as median and quartiles (Q1, Q3). Significant difference between the groups P < 0.001*** (PASI – psoriasis area and severity index) (n = 74)
Fig. 3
Fig. 3
Correlation between concentrations of serum fatty acid binding protein 5 (FABP5) and PASI (psoriasis area and severity index) (n = 74) (r = 0.42, P < 0.001) (n = 74)

Similar articles

Cited by

References

    1. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, Giannetti A, Girolomoni A. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007;157:68–73. doi: 10.1111/j.1365-2133.2007.07986.x. - DOI - PubMed
    1. Singh S, Young P, Armstrong AW. An update on psoriasis and metabolic syndrome: a meta-analysis of observational studies. PLoS ONE. 2017;18:e0181039. doi: 10.1371/journal.pone.0181039. - DOI - PMC - PubMed
    1. Strand V, Gonçalves J, Hickling TP, Jones HJ, Marshall L, Isaacs JD. Immunogenicity of biosimilars for rheumatic diseases, plaque psoriasis, and inflammatory bowel disease: a review from clinical trials and regulatory documents. BioDrugs. 2020;34:27–37. doi: 10.1007/s40259-019-00394-x. - DOI - PMC - PubMed
    1. Miller IM, Ellervik C, Yazdanyar S, Jemec GBE. Meta - analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69:1014–1024. doi: 10.1016/j.jaad.2013.06.053. - DOI - PubMed
    1. Magdaleno-Tapial J, Valenzuela-Oñate C, Ortiz-Salvador JM, Martínez-Doménech A, García-Legaz-Martínez M, Alonso-Carpio M, Tamarit-García JJ, et al. Prevalence of non-alcoholic fatty liver and liver fibrosis in patients with moderate-severe psoriasis: a cross-sectional cohort study. Australas J Dermatol. 2020;61:105–109. doi: 10.1111/ajd.13175. - DOI - PubMed